Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL (CHART-2)
EFFICACY AND SAFETY OF BONE MARROW-DERIVED MESENCHYMAL CARDIOPOIETIC CELLS (C3BS-CQR-1) FOR THE TREATMENT OF CHRONIC ISCHEMIC HEART FAILURE
Sponsor: Celyad Oncology SA
This PHASE3 trial investigates Heart Failure and is currently ongoing. Celyad Oncology SA leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Apr 2020 — Jul 2020 [monthly]
Unknown Status PHASE3
Status: Not Yet Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Apr 2020 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Celyad Oncology SA
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.